GSK Glaxosmithkline plc - ADR

$GSK 👀 Really like the structure developing on the 6M chart. GSK recently broke above a multi-year descending trendline and now appears to be coming back for a potential bullish pennant breakout retest around the $50 area. If this former resistance continues to hold as support, I’ll be watching for the next higher-low and continuation move. This is a long-term swing setup, so patience is key. 📈

$GSK $IONS Official PR dropped at the AH close Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

$GSK GSK Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer "today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway."

A rectal cancer treatment with no surgery, radiation or chemo just got FDA approval. $GSK Jemperli (MSI-H/dMMR, stage II/III): 71% of 154 patients needed no other treatment. Approved about 4 months early. Full data at ESMO Sun Oct 25. It's on the calendar 📅

$GSK Follow-up: UK drugmaker GSK (early Ris-Rez lung data, 18 Oct) won US accelerated approval for Jemperli in MSI-H/dMMR rectal cancer; on the trial's primary endpoint, independent review, 47% (54/116) had a 12-month complete response vs 68% by investigators. Niche vs a ~$106.86B market value ($49.525, 13:16 ET Oct 19, 2026): the biomarker is in about 5-10% of rectal cancers. No recurrence reported among responders after over two years' median follow-up, and 38 more short of 12 months already show complete response. Full data at ESMO this month.

$GSK What is going on here? Sold all minutes into open this morning. Ideas? Unexpected. GSK had been decent stock.

quiet clock on $GSK imo Nov 27 PDUFA, 36 days out, neladalkib in ALK positive lung cancer after a TKI Priority Review, Breakthrough and Orphan in hand, built to reach the brain and cover resistance mutations the older drugs miss trading 50.84 today, up 1.6 percent off a 50.02 close, and it came over in a 10.6 billion dollar deal for a reason ngl

https://stocktwits.com/news-articles/markets/equity/gsk-inovio-agios-sun-pharma-fda-decision-calendar-october/cZx8jI5RBML $GSK Inovio investors rallied shares to $14.74 on 3/31/2024 and the same value is likely to prevail on 10/30/26, reduced for shares issued, 4:1, but still 260% gains likely.

$GSK Follow-up: UK drugmaker GSK, a day after its 19 Oct 6-K on Jemperli's US rectal-cancer approval, won US approval for hepatitis B drug Hibsago, with a boxed warning for liver flares and sudden, possibly life-threatening low platelets. Label: adults without cirrhosis, on NrtI 6+ months, HBsAg ≤3,000 IU/mL; weekly platelet checks. GSK value ~$109.25B ($50.63/receipt, 20 Oct 2026 close at 16:00 ET). In return: a six-month course gave 19% functional cure (233/1,220) vs 0/614 on placebo. Other markets' decisions due in coming months.

$GSK Wolfe started coverage Friday with an Outperform and a 70 target, about 50% above where the shares closed. Consensus is still a Hold at 55.33, so Wolfe is roughly 27% above the street on a name down 20% over the last six months. Initiating that high on a beaten-up pharma stock is a pretty loud call.

The research continues and the AI overlords have been assigned another FDA decision to predict. Let's see how close it can get to it's predictions. $GSK — PDUFA: Oct. 26 Bepirovirsen for chronic hepatitis B. Priority Review + Breakthrough Therapy, backed by Phase 3 B-Well 1 & 2 where functional cure hit 19% vs. 0% with SoC alone. AI model call: • Approval probability: 95% • Estimated move on approval: +1.3% • Estimated move on miss: -1.7%

$GSK Excellent entry point. Strong support at 48.98. Worth $65 and they do have some mRNA expertise. Don't expect Moderna like action but up and to the right. Nice steady gainer for the future.